Accendra Health Reports Third-Quarter Loss and Trims Full-Year Outlook

Accendra Health (NYSE: ACH) reported third-quarter 2026 results and cut its full-year outlook, the company said in an 8-K filed Thursday, Nov. 5, 2026. The filing furnishes a press release and an earnings presentation under Items 2.02 and 7.01, and the information is not deemed filed for Section 18 purposes.

Quarterly results weaken

Net revenue for the quarter ended Sept. 30 was $601.8 million, down from $697.3 million a year earlier. The company posted a loss from continuing operations of $18.0 million, or $0.23 per share, compared with a loss of $5.6 million, or $0.07 per share, in the same quarter of 2025. Adjusted EBITDA, a non-GAAP measure, was $47.8 million, versus $92.2 million a year earlier.

For the nine months, net revenue was $1.84 billion, against $2.05 billion in the prior-year period. The loss from continuing operations widened to $113.5 million from $93.2 million. Free cash flow, also non-GAAP, was negative $21.3 million, compared with positive $80.0 million a year earlier.

Outlook cut

The company expects full-year net revenue at the bottom end of its prior outlook range of $2.45 billion to $2.55 billion. It said adjusted EBITDA could be as much as 30% lower than the $310 million midpoint of that range. The company said it cannot forecast GAAP results without unreasonable effort because of restructuring and acquisition charges.

Balance sheet and turnaround

Cash and cash equivalents stood at $26.6 million on Sept. 30, down from $282.0 million at the end of 2025. Total long-term debt excluding the current portion was $1.72 billion, and total deficit was $568.2 million. Chief Executive Kenny Gardner-Smith, who said in the release that he started several weeks earlier, said the company has identified four key areas for its transformation and that a value creation plan will be fully underway over the next several months. The company said it will share details in the coming months.

The release also cites a sale of the Products & Healthcare Services business and the company's ability to cure noncompliance with New York Stock Exchange listing standards among its forward-looking risks. The company did not give a timeline for curing that noncompliance in the filing.

Accendra will host a conference call Thursday, Nov. 5, at 5:00 p.m. ET.